Navigation Links
Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies
Date:10/2/2014

INDIANAPOLIS, Oct. 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)  announced today it will discontinue development of tabalumab­ -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns. ­­­­

In the ILLUMINATE 1 study, tabalumab did not achieve the primary endpoint, at either dose studied, of statistically significant improvement on SRI-5 (SLE Responder Index-5, a measurement of lupus disease activity and response), compared to standard of care therapy. In ILLUMINATE 2, the higher dose of tabalumab met this endpoint, the first time a lupus study has achieved this efficacy measure as a primary endpoint in a Phase 3 trial. Collectively, the data from these studies did not meet expectations for efficacy in the context of existing treatments. The overall safety profile showed a similar frequency of adverse events in patients treated with either tabalumab or standard of care. Lilly intends to submit these data for disclosure in appropriate upcoming scientific venues.

Given the overall efficacy results from these two pivotal Phase 3 studies, Lilly will not move forward with submissions to global regulators. Lilly will work with investigators to appropriately conclude these studies in the interest of patient safety.

"Although we were pleased that tabalumab met the criteria for statistically significant improvement in the SRI-5 endpoint in one of our trials, we are nonetheless disappointed that the overall results did not meaningfully improve the condition of the patients in these studies," said J. Anthony Ware, M.D., Senior Vice President, Product Development, Lilly Bio-Medicines. "The ILLUMINATE trials are the largest Phase 3 clinical studies in lupus to date, and we are hopeful that our contribution of the extensive data from these studies will advance knowledge to enhance treatment in this devastating illness. Lilly remains committed to developing potential new medicines for the treatment of autoimmune conditions, including lupus."

The decision to discontinue development of tabalumab for lupus is expected to result in a third-quarter charge to research and development expense of up to $75 million (pretax), or approximately $0.04 - $0.05 per share (after-tax).

About systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (also known as lupus) is a chronic, autoimmune disease that can damage any part of the body (skin, joints, and/or organs inside the body), and can range from mild to life-threatening. The Lupus Foundation of America estimates that up to 1.5 million people in the United States and 5 million people throughout the world have a form of lupus. Lupus strikes mostly women of childbearing age (15-44), though men, children, and teenagers also develop lupus. Most people develop lupus between the ages of 15-44.1

About Eli Lilly and Company (NYSE: LLY)
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.

P-LLY

This press release contains forward-looking statements about tabalumab as a potential treatment for systemic lupus erythematosus and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

1 Lupus Foundation of America: http://www.lupus.org/answers/entry/what-is-lupus (Accessed September 29, 2014)

Refer to:

Media: J. Scott MacGregor, jsmacgregor@lilly.com, +1-317-440-4699


Investors: Phil Johnson, johnson_philip_l@lilly.com, +1-317-655-6874

 

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lillys seventh Global Day of Service rallies 24,000 employees in nearly 60 countries
2. Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis
3. Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine
4. Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimers disease
5. European Commission grants Lilly and Boehringer Ingelheims insulin glargine product marketing authorisation in Europe
6. Lilly Highlights Latest Work in Diabetes Discovery and Development at 2014 European Association for the Study of Diabetes Annual Meeting
7. Global Diabetic Neuropathy Market 2014-2018: Key Vendors are Eli Lilly and Co, Janssen Pharmaceuticals and Pfizer Inc.
8. Lilly Reports Second-Quarter 2014 Results
9. The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
10. Global Type 1 Diabetes Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Co, Novo Nordisk and Sanofi-Aventis
11. Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
Breaking Medicine News(10 mins):